A Phase II, Multicenter, Open-Label Study of YM155 in Subjects With Unresectable Stage III or Metastatic (Stage IV) Melanoma

Trial Profile

A Phase II, Multicenter, Open-Label Study of YM155 in Subjects With Unresectable Stage III or Metastatic (Stage IV) Melanoma

Completed
Phase of Trial: Phase II

Latest Information Update: 06 Jun 2012

At a glance

  • Drugs Sepantronium bromide (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 06 Jun 2012 Actual end date (Jun 2007) added as reported by ClinicalTrials.gov.
    • 23 Oct 2007 Status changed from in progress to completed.
    • 12 Dec 2006 Status change
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top